Visara Inks Promising VIS-101 Exclusive License for Asia
NovaBridge’s ophthalmology subsidiary, Visara, has assigned its exclusive license for VIS-101 to Everest Medicines for development, manufacturing, and commercialization...
Cytek Deepens Devoted Commitment to Flow Cytometry Access
Cytek Biosciences has launched a two-part initiative with the International Society for Advancement of Cytometry to widen access to...
BridgeBio Reports Q3 2025 Financial Results & Updates
BridgeBio reported third-quarter revenue of $120.7 million, fueled by $108.1 million in U.S. net product sales of Attruby (acoramidis)...
Roche Purchases Shares in Tender Offer for 89bio, Inc.
Roche has secured control of 89bio through a completed tender offer at 14.50 dollars per share in cash plus...
argenx Q3 2025 Financial Results and Important Business Update
Argenx reported a pivotal third quarter: $1.13 billion in global net product sales, driven by the Vyvgart franchise across...
Cytek® Biosciences Deepens Commitment to Flow Cytometry
Cytek Biosciences has launched a two-part initiative with the International Society for Advancement of Cytometry to expand access to...
BridgeBio Reports Q3 2025 Financial Results & Updates
BridgeBio reported third-quarter revenue of $120.7 million, anchored by $108.1 million in U.S. net product sales from Attruby (acoramidis)...
Argenx Data Shows Remarkable VYVGART Benefit for MG Patients
Argenx presented a sweep of new Vyvgart data at AANEM/MGFA 2025, headlined by the phase 3 ADAPT SERON trial...
Ianalumab Reduces Sjögren’s Disease Activity in Phase III
Novartis reported positive Phase 3 results for ianalumab in Sjögren’s disease, with the 300 mg monthly subcutaneous regimen meeting...
New Hope: Rosnilimab Trial Shows Positive Arthritis Results
AnaptysBio reported late-breaking results from its 424-patient Phase 2b RA study showing that rosnilimab, a selective pathogenic T cell...